Developer docs
API playgroundTry for free, no card

Search company profiles

BioSkryb Genomics

Full company profile

uuid00009f3

Namestring
BioSkryb Genomics
Legal namestring
Bioskryb, Inc.
Websiteurl
bioskryb.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

BioSkryb Genomics is a US-based life sciences tools company founded in 2018 and headquartered in Durham, North Carolina, that develops and commercializes single-cell whole genome amplification and multiomics products for research, translational, and diagnostic-adjacent applications. Its core technology is Primary Template-directed Amplification (PTA), a patented isothermal whole genome amplification method using phi29 DNA polymerase with exonuclease-resistant terminators that achieves greater than 97% single-cell genome coverage and substantially higher uniformity than legacy WGA methods (DOP-PCR, MDA, MALBAC, LIANTI). The commercial portfolio includes ResolveDNA kits (single-cell DNA sequencing), ResolveOME kits (joint whole genome and full-length transcriptome from the same cell), the BaseJumper bioinformatics platform with embedded BaseJumper AI (LLM-enabled QC, variant calling, and report generation available as cloud or on-premise), ResolveSEQ application kits (MRD, ScreenHT high-throughput SNV screening, LongRead), and ResolveServices contract research services. A femtogram-scale sensitivity claim positions the technology to address 'quantity not sufficient' samples that account for up to 30% of high-volume diagnostic workflows.

The company sells primarily to biopharmaceutical companies, academic and research institutions, diagnostic developers, and AI/ML companies, with named reference customers including Beam Therapeutics, Falcon Therapeutics, Praxis Genomics, Harvard Medical School, Boston Children's Hospital, Duke University, University of Massachusetts Medical School, the Hubrecht Institute, and Oregon Health & Science University. Go-to-market is a hybrid model: direct enterprise sales in seven European countries (UK, Germany, Austria, Switzerland, Belgium, Luxembourg, Netherlands), with a global distributor network covering the rest of EMEA and Asia-Pacific including named partners in Italy, France, Iberia, Nordics, Israel, Poland, China, Japan, Korea, Australia, New Zealand, India, and Southeast Asia. Pricing is quote-based and not publicly disclosed; revenue streams comprise one-time kit and consumable sales, professional services through ResolveServices, and data monetization via AI dataset partnerships. Recent strategic activity in 2024–2025 includes partnerships with Human Cell Atlas, Tecan, Ultima Genomics, 1Cell.Ai, and Eremid Genomic Services, an exclusive methylation IP license, and multiple product launches extending into MRD and long-read applications.

Short descriptiontext

BioSkryb Genomics develops patented single-cell whole genome amplification (PTA) and multiomics products — ResolveDNA, ResolveOME, BaseJumper, and ResolveSEQ kits and services — serving biopharma, academic researchers, diagnostic developers, and AI/ML companies globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single-cell genomics, whole genome amplification, multiomics analysis, single-cell sequencing kits, bioinformatics platform
Industry3 codes
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Single-Cell Genomics Tools and Reagents
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales (Kits and Consumables)
TypeOne Time License
Description

Sale of ResolveDNA and ResolveOME whole genome amplification kits, library preparation reagents, bead purification kits, and related consumables. Available in 96 and 384 reaction formats.

bioskryb.com
2Contract Services (ResolveServices)
TypeProfessional Services
Description

End-to-end single-cell sequencing services including cell sorting, amplification, library preparation, sequencing, and bioinformatics analysis. Managed by PhD scientists with customizable project specifications.

bioskryb.com
3AI Dataset Partnerships
TypeData Monetisation
Description

Partnership with biopharma and AI/ML companies to provide high-fidelity single-cell multiomic training datasets for AI model development.

bioskryb.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1ResolveDNA
Description

Whole genome amplification kits for single-cell DNA sequencing

bioskryb.com
+6 more records
Core offering1 text field

BioSkryb Genomics develops and sells single-cell whole genome amplification kits (ResolveDNA, ResolveOME), sequencing services (ResolveSEQ MRD, ScreenHT, LongRead), and the BaseJumper bioinformatics platform, all powered by its patented Primary Template-directed Amplification (PTA) technology. The offering enables researchers to capture >97% of the genome along with full-length transcriptome and surface protein data from the same single cell in a single-day workflow.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • >97% genome coverage from single cells
+2 more records
Product overview1 text field

BioSkryb Genomics offers a platform-plus-products architecture centered on Primary Template-directed Amplification (PTA) technology. The core portfolio includes ResolveDNA for single-cell DNA sequencing, ResolveOME for single-cell multiomics (simultaneous DNA and RNA), and BaseJumper as the bioinformatics platform for QC analysis and data interpretation. The ResolveSEQ product line extends the platform with specialized applications including MRD (Minimal Residual Disease) detection, ScreenHT high-throughput screening, and LongRead sequencing. ResolveServices provides contract sequencing access to these technologies. BaseJumper is available as cloud-based (BaseJumper Cloud) or on-premise (BaseJumper Local) deployment. All products are designed to integrate with Illumina sequencing platforms.

Product and service5 records
1ResolveDNA
CategorySingle-cell whole genome amplification kits
Description

PTA-based whole genome amplification kit that reproducibly recovers greater than 95% of genomes from single cells with industry-leading uniformity and accuracy. Supports up to 384 reactions per kit and is designed for single-cell DNA sequencing researchers in academic, biopharma, and diagnostic settings.

2ResolveOME
CategorySingle-cell multiomics amplification kits
Description

Unified single-cell whole genome and transcriptome amplification kit that provides greater than 97% genomic coverage combined with full-length mRNA transcriptome analysis from the same single cell in a single-day, automation-compatible workflow. Available in 96 and 384 reaction formats.

3BaseJumper
CategoryBioinformatics software platform
Description

Cloud-based and local bioinformatics platform for single-cell multiomic data analysis, quality control, variant detection, custom variant models, and AI/ML training data preparation. Includes BaseJumper AI with LLM-enabled workflows for natural language interaction with genomic data.

4ResolveSEQ MRD
CategorySingle-cell sequencing services
Description

Single-cell DNA sequencing service and assay for minimal residual disease discovery and monitoring in hematologic malignancies, enabling more complete characterization of residual disease cells to support therapy selection.

5ResolveSEQ ScreenHT
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-07
Description

BioSkryb Certified Service Provider for ResolveSEQ LongRead Early Access Program. Eremid provides specialty high-complexity genomics contract research organization services.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-04-25
Description

Introduced high-throughput single-cell workflow combining BioSkryb's 384-well format ResolveOME kit with Tecan's automation platforms for sequencing-ready libraries in under ten hours.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-24
Description

Strategic partnership to co-develop and commercialize next-generation single cell multi-omic solutions. Combines BioSkryb's PTA-based single-cell technology with 1Cell.Ai's single cell precision diagnostics capabilities.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-04-23
Description

Joint grant program to advance oncology research. Provides researchers with access to BioSkryb's multi-omic platforms combined with Ultima Genomics' sequencing technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-26
Description

Partnership to increase global access to BioSkryb's single-cell multiomics technology. Human Cell Atlas is a global consortium creating reference maps of all human cells.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Dominant sequencing platform provider whose instruments are required downstream of BioSkryb's kits. Also offers adjacent single-cell and multiomics products and partnership ecosystems that intersect with BioSkryb's value chain.

TypeEmerging player
Description

Sequencing platform competitor to Illumina that could become an alternative downstream platform for BioSkryb's kits; represents both a potential partnership vector and a hedging opportunity against Illumina dependency.

TypeBroad incumbent
Description

Dominant single-cell sequencing platform (Chromium) with droplet-based partitioning for DNA and RNA. Directly competes with BioSkryb's ResolveDNA/ResolveOME in single-cell genomics, with much larger scale, broader installed base, and integrated instruments/reagents.

TypeDirect peer
Description

Single-cell DNA sequencing and multiomics platform (Tapestri) focused on oncology, MRD, and genomic profiling. Overlaps directly with BioSkryb's ResolveSEQ MRD application and ResolveOME multiomics positioning.

TypeEmerging player
Description

Single-cell sequencing with combinatorial indexing approach (Evercode), competing in single-cell RNA and multiomics. Targets similar academic/biopharma customers as BioSkryb but with different chemistry architecture.

TypeEmerging player
Description

Sequencing platform that already has an active partnership with BioSkryb for oncology grant programs. A potential alternative sequencing ecosystem for ResolveSEQ and ResolveOME products.

7Takara Bio (SMART-seq)
TypeBroad incumbent
Description

Provides SMART-seq single-cell RNA and emerging multiomics kits; competes with ResolveDNA and ResolveOME in academic and translational research, particularly for full-length transcriptome workflows.

TypeEmerging player
Description

Single-cell multiomics platform (PythoN, GEXSCOPE) with strong APAC distribution. Competes with BioSkryb in academic/biopharma single-cell applications and relevant given BioSkryb's APAC distributor network.

TypeBroad incumbent
Description

BD's Rhapsody single-cell multiomics platform competes with BioSkryb's ResolveDNA/ResolveOME in academic and translational research markets. Backed by a large life sciences conglomerate with extensive distribution.

TypeOthers
Description

Long-read sequencing platform with single-cell Iso-Seq and HiFi applications. Relevant as a potential complementary downstream for BioSkryb's ResolveSEQ LongRead early-access product.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioSkryb Genomics

Single-Cell Genomics Tools and Reagentsbioskryb.com

BioSkryb Genomics develops patented single-cell whole genome amplification (PTA) and multiomics products — ResolveDNA, ResolveOME, BaseJumper, and ResolveSEQ kits and services — serving biopharma, academic researchers, diagnostic developers, and AI/ML companies globally.

What BioSkryb Genomics does

BioSkryb Genomics is a US-based life sciences tools company founded in 2018 and headquartered in Durham, North Carolina, that develops and commercializes single-cell whole genome amplification and multiomics products for research, translational, and diagnostic-adjacent applications. Its core technology is Primary Template-directed Amplification (PTA), a patented isothermal whole genome amplification method using phi29 DNA polymerase with exonuclease-resistant terminators that achieves greater than 97% single-cell genome coverage and substantially higher uniformity than legacy WGA methods (DOP-PCR, MDA, MALBAC, LIANTI). The commercial portfolio includes ResolveDNA kits (single-cell DNA sequencing), ResolveOME kits (joint whole genome and full-length transcriptome from the same cell), the BaseJumper bioinformatics platform with embedded BaseJumper AI (LLM-enabled QC, variant calling, and report generation available as cloud or on-premise), ResolveSEQ application kits (MRD, ScreenHT high-throughput SNV screening, LongRead), and ResolveServices contract research services. A femtogram-scale sensitivity claim positions the technology to address 'quantity not sufficient' samples that account for up to 30% of high-volume diagnostic workflows.

The company sells primarily to biopharmaceutical companies, academic and research institutions, diagnostic developers, and AI/ML companies, with named reference customers including Beam Therapeutics, Falcon Therapeutics, Praxis Genomics, Harvard Medical School, Boston Children's Hospital, Duke University, University of Massachusetts Medical School, the Hubrecht Institute, and Oregon Health & Science University. Go-to-market is a hybrid model: direct enterprise sales in seven European countries (UK, Germany, Austria, Switzerland, Belgium, Luxembourg, Netherlands), with a global distributor network covering the rest of EMEA and Asia-Pacific including named partners in Italy, France, Iberia, Nordics, Israel, Poland, China, Japan, Korea, Australia, New Zealand, India, and Southeast Asia. Pricing is quote-based and not publicly disclosed; revenue streams comprise one-time kit and consumable sales, professional services through ResolveServices, and data monetization via AI dataset partnerships. Recent strategic activity in 2024–2025 includes partnerships with Human Cell Atlas, Tecan, Ultima Genomics, 1Cell.Ai, and Eremid Genomic Services, an exclusive methylation IP license, and multiple product launches extending into MRD and long-read applications.

BioSkryb Genomics firmographics

Firmographics
Name
BioSkryb Genomics
Legal name
Bioskryb, Inc.
Website
https://bioskryb.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
BioSkryb Genomics develops patented single-cell whole genome amplification (PTA) and multiomics products — ResolveDNA, ResolveOME, BaseJumper, and ResolveSEQ kits and services — serving biopharma, academic researchers, diagnostic developers, and AI/ML companies globally.
Ownership category
akta.pro rank

BioSkryb Genomics industry classification

Industry
Product category
Single-Cell Genomics Tools and Reagents
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Single-cell genomics
  • Whole genome amplification
  • Multiomics analysis
  • Single-cell sequencing kits
  • Bioinformatics platform

Where BioSkryb Genomics is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioSkryb Genomics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales (Kits and Consumables): Sale of ResolveDNA and ResolveOME whole genome amplification kits, library preparation reagents, bead purification kits, and related consumables. Available in 96 and 384 reaction formats.
  2. Contract Services (ResolveServices): End-to-end single-cell sequencing services including cell sorting, amplification, library preparation, sequencing, and bioinformatics analysis. Managed by PhD scientists with customizable project specifications.
  3. AI Dataset Partnerships: Partnership with biopharma and AI/ML companies to provide high-fidelity single-cell multiomic training datasets for AI model development.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

BioSkryb Genomics product offering

Product offering

Core offering

BioSkryb Genomics develops and sells single-cell whole genome amplification kits (ResolveDNA, ResolveOME), sequencing services (ResolveSEQ MRD, ScreenHT, LongRead), and the BaseJumper bioinformatics platform, all powered by its patented Primary Template-directed Amplification (PTA) technology. The offering enables researchers to capture >97% of the genome along with full-length transcriptome and surface protein data from the same single cell in a single-day workflow.

Product overview

BioSkryb Genomics offers a platform-plus-products architecture centered on Primary Template-directed Amplification (PTA) technology. The core portfolio includes ResolveDNA for single-cell DNA sequencing, ResolveOME for single-cell multiomics (simultaneous DNA and RNA), and BaseJumper as the bioinformatics platform for QC analysis and data interpretation. The ResolveSEQ product line extends the platform with specialized applications including MRD (Minimal Residual Disease) detection, ScreenHT high-throughput screening, and LongRead sequencing. ResolveServices provides contract sequencing access to these technologies. BaseJumper is available as cloud-based (BaseJumper Cloud) or on-premise (BaseJumper Local) deployment. All products are designed to integrate with Illumina sequencing platforms.

Differentiator

Problem solved

Functional benefit

Brands

  • ResolveDNA: Whole genome amplification kits for single-cell DNA sequencing
  • ResolveOME
  • BaseJumper
  • ResolveServices
  • ResolveSEQ MRD
  • ResolveSEQ ScreenHT
  • ResolveSEQ LongRead

Products and services

  • ResolveDNA PTA-based whole genome amplification kit that reproducibly recovers greater than 95% of genomes from single cells with industry-leading uniformity and accuracy. Supports up to 384 reactions per kit and is designed for single-cell DNA sequencing researchers in academic, biopharma, and diagnostic settings.
  • ResolveOME Unified single-cell whole genome and transcriptome amplification kit that provides greater than 97% genomic coverage combined with full-length mRNA transcriptome analysis from the same single cell in a single-day, automation-compatible workflow. Available in 96 and 384 reaction formats.
  • BaseJumper Cloud-based and local bioinformatics platform for single-cell multiomic data analysis, quality control, variant detection, custom variant models, and AI/ML training data preparation. Includes BaseJumper AI with LLM-enabled workflows for natural language interaction with genomic data.
  • ResolveSEQ MRD Single-cell DNA sequencing service and assay for minimal residual disease discovery and monitoring in hematologic malignancies, enabling more complete characterization of residual disease cells to support therapy selection.
  • ResolveSEQ ScreenHT

Quantifiable outcome

  • >97% genome coverage from single cells
  • +2 more outcomes

Companies that use BioSkryb Genomics

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

BioSkryb Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature5 records

BioSkryb Genomics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Eremid Genomic ServicesminorStrategic or Co-development Partner · 7 October 2025BioSkryb Certified Service Provider for ResolveSEQ LongRead Early Access Program. Eremid provides specialty high-complexity genomics contract research organization services.
  • Tecan GroupcoreTechnology or Integration · 25 April 2025Introduced high-throughput single-cell workflow combining BioSkryb's 384-well format ResolveOME kit with Tecan's automation platforms for sequencing-ready libraries in under ten hours.
  • 1Cell.AicoreStrategic or Co-development Partner · 24 April 2025Strategic partnership to co-develop and commercialize next-generation single cell multi-omic solutions. Combines BioSkryb's PTA-based single-cell technology with 1Cell.Ai's single cell precision diagnostics capabilities.
  • Ultima GenomicsminorGTM or Marketing Partner · 23 April 2025Joint grant program to advance oncology research. Provides researchers with access to BioSkryb's multi-omic platforms combined with Ultima Genomics' sequencing technology.
  • Human Cell AtlascoreStrategic or Co-development Partner · 26 September 2024Partnership to increase global access to BioSkryb's single-cell multiomics technology. Human Cell Atlas is a global consortium creating reference maps of all human cells.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

BioSkryb Genomics competitors and assessment

Company assessment

Broad incumbents

  • Illumina: Dominant sequencing platform provider whose instruments are required downstream of BioSkryb's kits. Also offers adjacent single-cell and multiomics products and partnership ecosystems that intersect with BioSkryb's value chain.
  • 10x Genomics: Dominant single-cell sequencing platform (Chromium) with droplet-based partitioning for DNA and RNA. Directly competes with BioSkryb's ResolveDNA/ResolveOME in single-cell genomics, with much larger scale, broader installed base, and integrated instruments/reagents.
  • Takara Bio (SMART-seq): Provides SMART-seq single-cell RNA and emerging multiomics kits; competes with ResolveDNA and ResolveOME in academic and translational research, particularly for full-length transcriptome workflows.
  • BD (BD Biosciences - Rhapsody): BD's Rhapsody single-cell multiomics platform competes with BioSkryb's ResolveDNA/ResolveOME in academic and translational research markets. Backed by a large life sciences conglomerate with extensive distribution.

Emerging players

  • Element Biosciences: Sequencing platform competitor to Illumina that could become an alternative downstream platform for BioSkryb's kits; represents both a potential partnership vector and a hedging opportunity against Illumina dependency.
  • Parse Biosciences: Single-cell sequencing with combinatorial indexing approach (Evercode), competing in single-cell RNA and multiomics. Targets similar academic/biopharma customers as BioSkryb but with different chemistry architecture.
  • Ultima Genomics: Sequencing platform that already has an active partnership with BioSkryb for oncology grant programs. A potential alternative sequencing ecosystem for ResolveSEQ and ResolveOME products.
  • Singleron Biotechnologies: Single-cell multiomics platform (PythoN, GEXSCOPE) with strong APAC distribution. Competes with BioSkryb in academic/biopharma single-cell applications and relevant given BioSkryb's APAC distributor network.

Direct peers

  • Mission Bio: Single-cell DNA sequencing and multiomics platform (Tapestri) focused on oncology, MRD, and genomic profiling. Overlaps directly with BioSkryb's ResolveSEQ MRD application and ResolveOME multiomics positioning.

Others

  • PacBio: Long-read sequencing platform with single-cell Iso-Seq and HiFi applications. Relevant as a potential complementary downstream for BioSkryb's ResolveSEQ LongRead early-access product.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BioSkryb Genomics social profiles

Digital presence

BioSkryb Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioSkryb Genomics leadership team

Management profile

Number of profiles

Profiles8 records

BioSkryb Genomics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioSkryb Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioSkryb Genomics

What does BioSkryb Genomics do?

BioSkryb Genomics develops and sells single-cell whole genome amplification kits (ResolveDNA, ResolveOME), sequencing services (ResolveSEQ MRD, ScreenHT, LongRead), and the BaseJumper bioinformatics platform, all powered by its patented Primary Template-directed Amplification (PTA) technology. The offering enables researchers to capture >97% of the genome along with full-length transcriptome and surface protein data from the same single cell in a single-day workflow.

Is BioSkryb Genomics a public or private company?

BioSkryb Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was BioSkryb Genomics founded?

BioSkryb Genomics was founded in 2018. It employs 11 to 50 people.

Where is BioSkryb Genomics based?

BioSkryb Genomics is headquartered in Durham, United States, in the North America region.

How does BioSkryb Genomics make money?

Three revenue lines are on record. Product Sales (Kits and Consumables) is the primary driver. The others are contract Services (ResolveServices) and AI Dataset Partnerships.

Who are BioSkryb Genomics's main competitors?

Broad incumbents on record are Illumina, 10x Genomics, Takara Bio (SMART-seq) and BD (BD Biosciences - Rhapsody). Emerging players are Element Biosciences, Parse Biosciences, Ultima Genomics and Singleron Biotechnologies. Mission Bio is listed as a direct peer. PacBio is listed as an others.

Does BioSkryb Genomics have an API?

No public API is recorded for BioSkryb Genomics.

What industry is BioSkryb Genomics in?

BioSkryb Genomics's product category is Single-Cell Genomics Tools and Reagents. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizBioSkryb Genomics Names William Evans CEO to Advance Clinical ApplicationsBioSkryb Genomics has appointed William E. Evans as its new chief executive officer, succeeding Suresh Pisharody who left the company to pursue other opportunities. Evans, a former CEO of St. Jude Children’s Research Hospital, will lead the Durham-based firm's efforts to expand its single-cell and multiomic technologies into clinical applications. The leadership transition aims to advance the company's commercial and scientific development in oncology, neurology, and cell therapy research.MorningstarBioSkryb Genomics Names William E. Evans, Pharm.D. as Chief Executive OfficerBioSkryb Genomics appointed William E. Evans, Pharm.D., as CEO, succeeding Suresh Pisharody. Evans, a former St. Jude CEO, brings four decades of leadership in pharmacogenomics and has served on the company's board since 2019. He will guide the company's next phase of growth, including clinical applications and AI-oriented multiomic programs.HRD AmericaBiotech employer learns California law follows the contract across state linesA North Carolina court ruled that BioSkryb Genomics is liable to co-founder Jason A.A. West for attempting to enforce nonsolicitation clauses void under California law, despite the employment occurring in North Carolina. The decision establishes that California's statutory ban on enforcing such restrictive covenants applies extraterritorially when a contract specifies California as the governing law. This ruling imposes potential damages and attorney's fees on employers who rely on choice-of-law clauses without considering the strictness of the selected state's regulations.Roots AnalysisMultiomics Market Size, Share, Trends, & Insights Report, 2035A market research report forecasts the global multiomics market will grow from USD 3.10 billion in 2025 to USD 12.65 billion by 2035, driven by advancements in single-cell analysis and AI-driven data integration. Key industry participants including MultiOmic Health, Singleron Biotechnologies, and BioSkryb are actively expanding their capabilities through funding, partnerships, and new product launches to address growing demand in precision medicine and drug discovery.News-MedicalBioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hoursBioSkryb Genomics and Tecan introduced a single-cell multiomics workflow combining BioSkryb's ResolveOME kit with Tecan's Uno Single Cell Dispenser. The integrated solution produces sequencing-ready libraries in under ten hours, reducing reliance on FACS. The partnership aims to scale single-cell analysis for cancer research and drug development.YahooBioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hoursBioSkryb Genomics and Tecan introduced a single-cell multiomics workflow combining BioSkryb's ResolveOME kit with Tecan's Uno Single Cell Dispenser. The integrated solution processes hundreds to thousands of cells in under ten hours, reducing reliance on FACS. The partnership aims to make scalable single-cell analysis accessible to more labs.YahooBioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hoursBioSkryb Genomics and Tecan introduced a single-cell multiomics workflow combining BioSkryb's ResolveOME kit with Tecan's Uno Single Cell Dispenser. The integrated solution processes hundreds to thousands of cells in under ten hours, reducing reliance on FACS. The partnership aims to scale single-cell analysis for cancer research and drug development.Business Wire BlogBioSkryb Genomics and Ultima Genomics Launch Collaborative Grant Program to Advance Oncology ResearchBioSkryb Genomics and Ultima Genomics announced a collaborative grant program to advance oncology research, combining single-cell amplification with high-throughput sequencing. The program offers grants worth up to 2,000 single-cell genomes at no cost, with applications due June 20, 2025 and results announced July 15, 2025.BioskrybThe Future of MultiomicsCharles Gawad, CSO of BioSkryb Genomics, outlines key trends for multiomics research in 2025, highlighting the shift from bulk to single-cell resolution due to improved technologies and lower sequencing costs. He anticipates advancements in acquiring larger fractions of nucleic acid content, utilizing long-read sequencing, and integrating protein measurements to better understand tissue biology.